Patents by Inventor Christine Fritsch

Christine Fritsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases
    Publication number: 20140275089
    Abstract: The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and inhibitors of Heat Shock Protein 90, and the uses of such combinations in the treatment of proliferative diseases, more specifically PI3K dependent diseases, more specifically PI3K-alpha dependent diseases.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 18, 2014
    Inventors: Xizhong Huang, Cornelia Quadt, Hui-Qin Wang, Christine Fritsch, Christian René Schnell
  • COMBINATION OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A MTOR INHIBITOR
    Publication number: 20140066474
    Abstract: The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mTOR) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mTOR) kinase dependent diseases.
    Type: Application
    Filed: April 23, 2012
    Publication date: March 6, 2014
    Applicant: NOVARTIS AG
    Inventors: Christine Fritsch, Carlos Garcia-Echeverria, Xizhong Huang, Sauveur-Michel Maira
  • Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway
    Publication number: 20140057904
    Abstract: The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
    Type: Application
    Filed: October 30, 2013
    Publication date: February 27, 2014
    Inventors: Carlos Garcia-Echeverria, Sauveur-Michel Maira, Darrin Stuart, Susan Wee, Christine Fritsch, Tobi Nagel
  • Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
    Publication number: 20130209461
    Abstract: A method for treating an Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members comprising administering a therapeutically effective amount of a compound of formula (I) alone or in combination with an EGFR modulator, to a warm-blooded animal in need thereof; combinations comprising the compound of formula (I) and an EGFR modulator for the treatment of said diseases; and pharmaceutical preparations for the treatment of said diseases comprising the compound of formula (I), alone or in combination with an EGFR modulator.
    Type: Application
    Filed: November 7, 2011
    Publication date: August 15, 2013
    Applicant: NOVARTIS AG
    Inventors: Saskia Maria Brachmann, Christine Fritsch, Sauveur-Michel Maira, Christian Rene Schnell, Carlos Garcia-Echeverria
  • COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) A MODULATOR OF RAS/RAF/MEK PATHWAY
    Publication number: 20110105521
    Abstract: The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
    Type: Application
    Filed: July 10, 2009
    Publication date: May 5, 2011
    Applicant: NOVARTIS AG
    Inventors: Carlos Garcia-Echeverria, Sauveur-Michel Maira, Darrin Stuart, Susan Wee, Christine Fritsch, Tobi Nagel
  • IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS
    Publication number: 20100105696
    Abstract: The invention relates to the use of compounds of formula (I) in the treatment of mammalian target of rapamycin (mTOR) kinase dependent diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of said diseases.
    Type: Application
    Filed: February 19, 2008
    Publication date: April 29, 2010
    Applicant: NOVARTIS AG
    Inventors: Carlos Garcia-Echeverria, Paul Leslie Nicklin, Leon Murphy, Sauveur-Michel Maira, Peter Finan, Christine Fritsch, Saskia Maria Brachmann